Company Overview and News
* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia (1-0)
Welcome to the Q3 2017 Vanda Pharmaceuticals Inc. Earnings Conference Call. My name is Leslie and I will be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. (1-0)
The bioscience catalyst series seeks to help readers making sense of the notable life science runners. (61-1)
WASHINGTON, Oct. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit Conference in New York City on Wednesday, October 11, 2017. (1-0)
Great Point Partners Llc has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 486,757,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Great Point Partners Llc's top holdings are Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) , Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) , Zogenix, Inc. (NASDAQ:ZGNX) , PTC Therapeutics, Inc. (362-10)
WASHINGTON, Oct. 2, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the results of the Phase II study of tradipitant in atopic dermatitis will be presented at the 9th World Congress of Itch in Wroclaw Poland as a late breaking entry in the scientific poster forum on October 16 and 17. On September 13, 2017, Vanda announced that tradipitant improved both itch and disease severity in patients with atopic dermatitis. (1-0)
If you want a Stock Review on VNDA, ACAD, ACHN, or AGIO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com monitors Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). These stocks belong to the Biotechnology space, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures. (175-0)
WASHINGTON, Sept. 13, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced results from an 8-week randomized Phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis. Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity.
* Vanda Pharmaceuticals Inc - announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus
-- Worst Itch Visual Analog Scale (Worst Itch VAS): Tradipitant vs. Placebo p=0.019 -- Scoring Atopic Dermatitis (SCORAD): Tradipitant vs. Placebo p=0.008 Management to host conference call on Thursday, September 14 at 8:30 AM ET
Vascular Biogenics Ltd. (VBLT - Free Report) was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.05 to $4.65 in the past one-month time frame.
Welcome to the Q2 2017 Vanda Pharmaceuticals Earnings Conference Call. My name is Victoria and I will be your operator for today's call. At this time, all participants are in a listen only mode. And later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded.
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton